LI Wei, ZHANG Hui-lai. Chemoimmunotherapy with Methotrexate, Cytarabine, Thiotepa, and Rituximab （MATRix Regimen） in Patients with Primary Central Nervous System Lymphoma[J]. Journal of Evidence-Based Medicine, 2018, 18(2): 74-77. DOI: 10.12019/j.issn.1671-5144.2018.02.005
|
Citation:
|
LI Wei, ZHANG Hui-lai. Chemoimmunotherapy with Methotrexate, Cytarabine, Thiotepa, and Rituximab （MATRix Regimen） in Patients with Primary Central Nervous System Lymphoma[J]. Journal of Evidence-Based Medicine, 2018, 18(2): 74-77. DOI: 10.12019/j.issn.1671-5144.2018.02.005
|
LI Wei, ZHANG Hui-lai. Chemoimmunotherapy with Methotrexate, Cytarabine, Thiotepa, and Rituximab （MATRix Regimen） in Patients with Primary Central Nervous System Lymphoma[J]. Journal of Evidence-Based Medicine, 2018, 18(2): 74-77. DOI: 10.12019/j.issn.1671-5144.2018.02.005
|
Citation:
|
LI Wei, ZHANG Hui-lai. Chemoimmunotherapy with Methotrexate, Cytarabine, Thiotepa, and Rituximab （MATRix Regimen） in Patients with Primary Central Nervous System Lymphoma[J]. Journal of Evidence-Based Medicine, 2018, 18(2): 74-77. DOI: 10.12019/j.issn.1671-5144.2018.02.005
|
DownLoad: